RECURRENT LUNG SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new drug duo in battle against Tough-to-Treat lung cancer
Disease control OngoingThis study tested whether adding a new drug called veliparib to an existing chemotherapy (temozolomide) works better for people with small cell lung cancer that has come back or stopped responding to prior treatment. The goal was to see if the combination could help control the c…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo aims to outsmart tough lung cancer
Disease control OngoingThis study is testing if adding an experimental drug called berzosertib (M6620) to standard chemotherapy (topotecan) works better than chemotherapy alone for adults whose small cell lung cancer has come back. The goal is to see if the combination can help control the cancer for l…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Scientists test Triple-Threat attack on Tough-to-Treat lung cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a new three-drug combination for small cell lung cancer that has returned after initial treatment. The combination includes a pill (tazemetostat), a chemotherapy (topotecan), and an immunotherapy (pembrolizumab), aimin…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC